Minocycline

Half-Life (t½)
PO: 15.5h · IV: 15.5h
Formula
C23H27N3O7
Molecular Weight
457.48 g/mol
PubChem CID
54675783
Aliases
Minocin

Pharmacological Mechanism

Tetracycline — 30S ribosomal inhibitor. Higher CNS penetration than doxycycline (anti-inflammatory neuro-applications studied). First-line for inflammatory acne; vestibular side effects (~10%) worse than doxycycline. PK (Minocin label 2024, capsule formulation): Cmax 2.1–5.1 µg/mL (avg 3.5 µg/mL), Tmax 1–4 h (avg 2.1 h), t½ 11.1–22.1 h (avg 15.5 h), oral absorption virtually complete (F ≈ 0.95). High-fat meal does not change extent of absorption but delays Tmax by 1 h. Highly lipophilic of the tetracyclines — good CSF + sebaceous-gland penetration.

Half-Life & Elimination Curve (PO: 15.5h · IV: 15.5h)

100%50%25%12.5%0%0h0×t½15.5h1×t½31h2×t½46.5h3×t½62h4×t½3.2d5×t½0×t½ (0h): 100% remaining (~0.821 mg/L)1×t½ (15.5h): 50% remaining (~0.411 mg/L)2×t½ (31h): 25% remaining (~0.205 mg/L)3×t½ (46.5h): 12.5% remaining (~0.103 mg/L)4×t½ (62h): 6.3% remaining (~51.3 µg/L)5×t½ (3.2d): 3.1% remaining (~25.7 µg/L)
Plasma (PO)t½ Decay (15.5h)
  • 0×t½0h100% (0.821 mg/L)
  • 1×t½15.5h50% (0.411 mg/L)
  • 2×t½31h25% (0.205 mg/L)
  • 3×t½46.5h12.5% (0.103 mg/L)
  • 4×t½62h6.3% (51.3 µg/L)
  • 5×t½3.2d3.1% (25.7 µg/L)
Elimination t½15.5h (PO)
Rate Constant (ke)0.0447 h⁻¹
Time to Peak (Tmax)3.25h
Est. Peak (Cmax)0.821 mg/L
Clearance (CL)4.47 L/h
97% Washout (5×t½)3.2d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References